Stock Taper 
DCTH
$16.34
▼ DOWN 0.31% (-0.05)
KEY STATISTICS
Market Cap$564.08 M
52w High$17.42
52w Low$8.12
Dividend Yield—
Frequency—
P/E1634.00
Volume491.05K
Shares Out.34.52M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Gerard J. Michel
COMPENSATION 2026
Salary$635,707
Stock Awards$0
Incentive Plan Pay$355,000
All Other Comp.$0
Total$5,765,258
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 3, 2018
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
156
PRICE TARGET
Target High$32.00
Target Low$17.00
Target Median$24.50
Target Consensus$24.50
UPCOMING EARNINGS
DateNov 3, 2026
DayTuesday
Rev. Est.$26.00M
NOV
3
TUE
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-12-27 | Reverse | 1:700 |
| 2019-12-24 | Reverse | 1:700 |
| 2019-10-22 | Reverse | 1:100 |
| 2018-05-02 | Reverse | 1:500 |
| 2017-11-06 | Reverse | 1:350 |
| 2016-07-21 | Reverse | 1:16 |
| 2014-04-09 | Reverse | 1:16 |
PRICE
$16.34 ▼ DOWN 0.31% (−$0.05)About Delcath Systems, Inc.
https://www.delcath.com ↗Delcath Systems, Inc. develops the HEPZATO KIT and CHEMOSAT system for targeted high-dose liver chemotherapy to treat primary and metastatic liver cancers in the U.S. and Europe.
INDUSTRY
Medical - Devices
A PRODUCT DELCATH SYSTEMS, INC. IS KNOWN FOR
HEPZATO KIT™
HEPZATO KIT™ is an FDA-approved, targeted drug-device combo delivering high-dose melphalan directly to the liver to treat metastatic uveal melanoma, minimizing systemic side effects, with commercial launch in 2024.
Revenue by Products
| Icon | PRODUCT | Q1-2023 | Q2-2023 | Q3-2023 | Q4-2023 |
|---|---|---|---|---|---|
 | Product | $597K | $495K ▼ | $434K ▼ | $539K ▲ |
 | Product and Service Other | $0 | $0 | $0 | — |
Revenue by Geography
| Map | REGION | Q1-2026 | Q2-2026 |
|---|---|---|---|
 | UNITED STATES | $23.25M | $27.16M ▲ |
 | NonUS | $1.75M | $1.97M ▲ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
67
LISTED HERE
14
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
39.56%
HOLDERS
178
TOP 12 OF 178 · RANKED BY POSITION SIZE
Rosalind Advisors, Inc.
Blackrock, Inc.
Vanguard Group Inc
Propel Bio Management, LLC
Geode Capital Management, LLC
State Street Corp
Nantahala Capital Management, LLC
Private Wealth Advisors, LLC
Millennium Management LLC
Goldman Sachs Group Inc
Algert Global LLC
Vivo Capital, LLC
RATINGS SNAPSHOT
Overall rating: B
Discounted Cash Flow3
Return On Equity3
Return On Assets3
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score3
INSIDER TRADES
★
DIRECTOR
Martell Bridget A
Purchase · 22.5K shares
2026-05-13
★
DIRECTOR
Aharon Gil
Purchase · 22.5K shares
2026-05-13
★
DIRECTOR
CZEREPAK ELIZABETH
Purchase · 22.5K shares
2026-05-13
★
DIRECTOR
Sylvester John Richard
Purchase · 22.5K shares
2026-05-13
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 3
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 AGL | $92.54 | COMPARE |
 BWAY | $14.30 | COMPARE |
 CERS | $2.65 | COMPARE |
 TCMD | $23.16 | COMPARE |
 NPCE | $14.41 | COMPARE |
 MASS | $10.73 | COMPARE |
 SENS | $9.33 | COMPARE |
 RXST | $7.05 | COMPARE |